Acute Programme
Hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP)
Pre-clinical/ResearchActive
Key Facts
Indication
Hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP)
Phase
Pre-clinical/Research
Status
Active
Company
About Santero Therapeutics
Santero Therapeutics is a private, preclinical-stage biotech tackling a major unmet need in chronic bacterial infections. The company's innovative platform targets the RelA/SpoT homolog (RSH) enzymes, a master switch for bacterial dormancy, with two distinct mechanisms: direct bactericidal activity and resensitization of dormant bacteria to standard-of-care antibiotics. Its lead program is focused on non-cystic fibrosis bronchiectasis (NCFB) patients with chronic Pseudomonas aeruginosa infection, a population with high morbidity and mortality, and it has broad potential across multiple chronic and acute refractory infections.
View full company profileTherapeutic Areas
Other Hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) Drugs
| Drug | Company | Phase |
|---|---|---|
| KV-001 | Kinvard Bio | Pre-clinical |